93 results
8-K
EX-99.1
TOVX
Theriva Biologics Inc
16 Apr 24
Regulation FD Disclosure
8:00am
innovation
SUMMARY
31 THERIVA OV PORTFOLIO HIGHLIGHTS Unique MOA enables multiple indications and combinations Highly differentiated OV designed
8-K
EX-99.1
TOVX
Theriva Biologics Inc
8 Jan 24
Regulation FD Disclosure
8:10am
Advancing founders’ decade of world leading OV innovation
40 Bayo - Puxan N et al. (2006) Role of the putative heparan sulfate glycosaminoglycan
8-K
EX-99.1
59yj4w7p
2 Aug 23
Regulation FD Disclosure
9:22am
424B5
5zgxrmr51xgt6p
5 Dec 22
Prospectus supplement for primary offering
4:05pm
424B3
jdg3 szm918ef
16 Sep 22
Prospectus supplement
4:15pm
8-K/A
EX-99.1
x33k31twmjlcv7nrv0o6
6 May 22
Completion of Acquisition or Disposition of Assets
5:22pm
8-K
f72oj
11 Mar 22
Synthetic Biologics Completes Acquisition of VCN Biosciences
8:06am
8-K
EX-99.1
reht e3sulougozxceu
11 Mar 22
Synthetic Biologics Completes Acquisition of VCN Biosciences
8:06am
8-K
EX-2.2
l635flvw4ln2lj kuw
11 Mar 22
Synthetic Biologics Completes Acquisition of VCN Biosciences
8:06am
8-K
EX-2.1
1m8j2tut2zge
14 Dec 21
Entry into a Material Definitive Agreement
8:05am
8-K
789ujdoy5cw7vgj8v
14 Dec 21
Entry into a Material Definitive Agreement
8:05am